scinapse is loading now...
Melek Erdem
8Publications
1H-index
1Citations
Publications 8
Newest
Published on Jan 1, 2019in Acta Haematologica 1.31
Melek Erdem1
Estimated H-index: 1
,
Özlem Tüfekçi6
Estimated H-index: 6
+ 2 AuthorsHale Ören14
Estimated H-index: 14
Source Cite
Published on Jun 8, 2019in Turkish Journal of Hematology 0.65
Özlem Tüfekçi6
Estimated H-index: 6
,
Şebnem Yılmaz8
Estimated H-index: 8
+ 2 AuthorsHale Ören14
Estimated H-index: 14
Source Cite
Published on Feb 1, 2018in Journal of Pediatric Hematology Oncology 1.06
Özlem Tüfekçi6
Estimated H-index: 6
,
Melek Erdem1
Estimated H-index: 1
+ 1 AuthorsŞebnem Yılmaz8
Estimated H-index: 8
Source Cite
Published on Oct 1, 2017in Journal of Pediatric Hematology Oncology 1.06
Özlem Tüfekçi6
Estimated H-index: 6
,
Şebnem Yılmaz Bengoa1
Estimated H-index: 1
+ 1 AuthorsHale Ören14
Estimated H-index: 14
Source Cite
Şebnem Yılmaz Bengoa1
Estimated H-index: 1
,
Eda Ataseven2
Estimated H-index: 2
+ 3 AuthorsHale Ören14
Estimated H-index: 14
The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute l...
1 Citations Source Cite
1